全球細胞和基因療法 CDMO 市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

全球細胞和基因治療 CDMO 市場需求預計將從 2022 年的 40.5 億美元增至 2030 年近 293.9 億美元，2023-2030 年研究期間CAGR為 28.11%。

細胞和基因療法合約開發和製造組織 (CDMO) 是代表其他生物製藥公司提供細胞和基因療法開發、製造和測試服務的專業公司。細胞和基因療法是先進的治療方法，涉及操縱或改造患者的細胞來治療或預防疾病。這些療法對治療各種疾病有著極大的希望，包括某些癌症、遺傳性疾病和其他嚴重疾病。

市場動態

在多種因素的推動下，細胞和基因治療合約開發和製造組織 (CDMO) 市場正在經歷顯著成長。作為各種疾病的創新療法，細胞和基因療法日益受到關注和投資，推動了對專業製造服務的需求。這些療法涉及的製造過程非常複雜，加上對專業知識和專門設施的需求，導致外包給 CDMO 的趨勢不斷上升。監管支持和合規性是關鍵的促進因素，因為細胞和基因療法的嚴格監管要求使得經驗豐富的 CDMO 在遵守標準方面擁有良好的記錄而備受追捧。 CDMO 提供的靈活性和可擴展性是影響市場的重要因素，使生物製藥公司能夠有效地適應臨床試驗進展和商業化需求。隨著細胞和基因治療領域的進步，對 CDMO 服務的需求預計將繼續成長，這些組織在支持創新療法的開發和製造方面發揮著至關重要的作用。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球細胞和基因治療 cdmo 市場的每個細分市場進行了包容性評估。細胞和基因治療 cdmo 產業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的細胞和基因治療 CDMO 市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。細胞和基因療法 CDMO 市場的主要參與者包括 Lonza、Catalent, Inc、Cytiva、Samsung Biologics、Thermo Fisher Scientific Inc.、Novartis AG、WuXi AppTec、AGC Biologics、OmniaBio、Rentschler Biopharma SE、Charles River Laboratories。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法論
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：細胞與基因治療 CDMO - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 按階段分析市場吸引力
  • 市場吸引力分析：按產品類型
  • 按指標進行的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球細胞和基因治療 CDMO 市場分析：按階段

• 分階段概覽
• 歷史和預測數據
• 按階段分析
• 臨床前
• 臨床

第 6 章：全球細胞與基因療法 CDMO 市場分析：依產品類型

• 概述：按產品類型
• 歷史和預測數據
• 分析：依產品類型
• 基因治療（體外、體內）
• 基因修飾細胞療法（CAR T 細胞療法、CAR-NK 細胞療法、TCR-T 細胞療法、其他）
• 細胞療法

第 7 章：全球細胞與基因療法 CDMO 市場分析：按適應症分類

• 按適應症概述
• 歷史和預測數據
• 按指標分析
• 腫瘤學
• 傳染性疾病
• 神經系統疾病
• 罕見疾病
• 其他

第 8 章：全球細胞和基因治療 CDMO 市場分析：按地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區國家/地區銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 9 章：細胞與基因療法 CDMO 公司的競爭格局

• 細胞和基因治療Cdmo市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 10 章：公司簡介

• 公司股份分析
• 市場集中度
• Lonza
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Catalent Inc
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Cytiva
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Samsung Biologics
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Thermo Fisher Scientific Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Novartis AG
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• WuXi AppTec
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• AGC Biologics
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• OmniaBio
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Rentschler Biopharma SE
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Charles River Laboratories
• 公司簡介
• 公司收入
• 產品
• 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

The global demand for Cell And Gene Therapy CDMO Market is presumed to reach the market size of nearly USD 29.39 BN by 2030 from USD 4.05 BN in 2022 with a CAGR of 28.11% under the study period 2023 - 2030.

Cell and Gene Therapy Contract Development and Manufacturing Organizations (CDMOs) are specialized companies that provide services for the development, manufacturing, and testing of cell and gene therapies on behalf of other biopharmaceutical companies. Cell and gene therapies are advanced therapeutic approaches that involve manipulating or engineering a patient's cells to treat or prevent diseases. These therapies hold great promise for various conditions, including certain cancers, genetic disorders, and other severe illnesses.

MARKET DYNAMICS

The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth driven by multiple factors. The increasing focus and investment in cell and gene therapies as innovative treatments for various diseases have propelled the demand for specialized manufacturing services. The complexity of the manufacturing process involved in these therapies, coupled with the need for expertise and specialized facilities, has led to a rising trend of outsourcing to CDMOs. Regulatory support and compliance are critical drivers, as the stringent regulatory requirements for cell and gene therapies make experienced CDMOs with a proven track record in adherence to standards highly sought after. Flexibility and scalability offered by CDMOs are essential factors influencing the market, enabling biopharmaceutical companies to adapt production to clinical trial progress and commercialization needs effectively. As the field of cell and gene therapy advances, the demand for CDMO services is expected to continue growing, with these organizations playing a crucial role in supporting the development and manufacturing of innovative therapies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell and gene therapy cdmo. The growth and trends of cell and gene therapy cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the cell and gene therapy cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Phase

• Pre-Clinical
• Clinical

By Product Type

• Gene Therapy (Ex-Vivo, In-Vivo)
• Gene-Modified Cell Therapy (Car T-Cell Therapies, Car-Nk Cell Therapy, Tcr-T Cell Therapy, Other)
• Cell Therapy

By Indication

• Oncology
• Infectious Diseases
• Neurological Disorders
• Rare Diseases
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cell And Gene Therapy CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cell And Gene Therapy CDMO market include Lonza, Catalent, Inc, Cytiva, Samsung Biologics, Thermo Fisher Scientific Inc., Novartis AG, WuXi AppTec, AGC Biologics, OmniaBio, Rentschler Biopharma SE, Charles River Laboratories. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . CELL AND GENE THERAPY CDMO - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Phase
  • 3.7.2 Market Attractiveness Analysis By Product Type
  • 3.7.3 Market Attractiveness Analysis By Indication
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY PHASE

• 5.1 Overview by Phase
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Phase
• 5.4 Pre-clinical Historic and Forecast Sales by Regions
• 5.5 Clinical Historic and Forecast Sales by Regions

6 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY PRODUCT TYPE

• 6.1 Overview by Product Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Product Type
• 6.4 Gene Therapy (Ex-vivo, In-vivo) Historic and Forecast Sales by Regions
• 6.5 Gene-Modified Cell Therapy (CAR T-cell Therapies, CAR-NK Cell Therapy, TCR-T Cell Therapy, Other) Historic and Forecast Sales by Regions
• 6.6 Cell Therapy Historic and Forecast Sales by Regions

7 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY INDICATION

• 7.1 Overview by Indication
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Indication
• 7.4 Oncology Historic and Forecast Sales by Regions
• 7.5 Infectious Diseases Historic and Forecast Sales by Regions
• 7.6 Neurological Disorders Historic and Forecast Sales by Regions
• 7.7 Rare Diseases Historic and Forecast Sales by Regions
• 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE CELL AND GENE THERAPY CDMO COMPANIES

• 9.1. Cell And Gene Therapy Cdmo Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF CELL AND GENE THERAPY CDMO INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Lonza
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Catalent Inc
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Cytiva
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Samsung Biologics
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Thermo Fisher Scientific Inc.
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Novartis AG
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. WuXi AppTec
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. AGC Biologics
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. OmniaBio
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Rentschler Biopharma SE
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments
• 10.13. Charles River Laboratories
  • 10.13.1. Company Overview
  • 10.13.2. Company Revenue
  • 10.13.3. Products
  • 10.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Phase (USD MN)
• Pre-clinical Market Sales by Geography (USD MN)
• Clinical Market Sales by Geography (USD MN)
• Analysis Market by Product Type (USD MN)
• Gene Therapy (Ex-vivo, In-vivo) Market Sales by Geography (USD MN)
• Gene-Modified Cell Therapy (CAR T-cell Therapies, CAR-NK Cell Therapy, TCR-T Cell Therapy, Other) Market Sales by Geography (USD MN)
• Cell Therapy Market Sales by Geography (USD MN)
• Analysis by Indication (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Infectious Diseases Market Sales by Geography (USD MN)
• Neurological Disorders Market Sales by Geography (USD MN)
• Rare Diseases Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Cell And Gene Therapy Cdmo Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Cell And Gene Therapy Cdmo Report
• Market Research Process
• Market Research Methodology
• Global Cell And Gene Therapy Cdmo Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Phase
• Market Attractiveness Analysis by Product Type
• Market Attractiveness Analysis by Indication
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Phase (USD MN)
• Pre-clinical Market Sales by Geography (USD MN)
• Clinical Market Sales by Geography (USD MN)
• Global Market Analysis by Product Type (USD MN)
• Gene Therapy (Ex-vivo, In-vivo) Market Sales by Geography (USD MN)
• Gene-Modified Cell Therapy (CAR T-cell Therapies, CAR-NK Cell Therapy, TCR-T Cell Therapy, Other) Market Sales by Geography (USD MN)
• Cell Therapy Market Sales by Geography (USD MN)
• Global Market Analysis by Indication (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Infectious Diseases Market Sales by Geography (USD MN)
• Neurological Disorders Market Sales by Geography (USD MN)
• Rare Diseases Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.